Dr. Andrew Puca has extensive experience in preclinical drug development, partnering with clients to optimize the translatability of their metabolic disease programs. Since joining CrownBio in 2016, Andrew’s scientific focus has been on translational animal models of cardiovascular and metabolic disease including obesity, type 2 diabetes, NAFLD/NASH, dysmetabolism, and diabetic nephropathy.

Andrew received his Ph.D. in Cellular and Molecular Biology from Università degli Studi di Siena and completed his postdoctoral research at Temple University, specializing in stem cell biology and regenerative medicine. He has over 10 years of translational research experience and has authored 15 publications.